抗体与PD-1/PD-L1蛋白质的分子相互作用
Sofia Vasilakaki1, Ioannis Vathiotis2, Emmanouil Panagiotou2
1Chemistry Department, National & Kapodistrian University of Athens, Panepistimiopolis, Athens, 15771, Greece.
Immunotherapy
|December 6, 2023
概括
针对编程细胞死亡蛋白1 (PD-1) 和其配体 (PD-L1) 的抗体表现出明显的蛋白质-蛋白质相互作用. 结合亲和力的这些差异可能解释了这些免疫检查点抑制剂观察到的不同临床疗效.
科学领域:
- 免疫学 免疫学 免疫学
- 结构生物学 结构生物学
- 计算生物学 计算生物学
背景情况:
- 针对PD-1/PD-L1通路的免疫检查点抑制剂在癌症治疗中至关重要.
- 了解抗体结合的分子基础对于优化治疗策略至关重要.
- 临床反应的变化表明抗体-标相互作用的差异.
研究的目的:
- 为了比较PD-1和PD-L1抗体与其点的蛋白质-蛋白质相互作用.
- 阐明结构特征如何影响抗体结合亲和力和临床行为.
- 为了研究 pembrolizumab,nivolumab,durvalumab,atezolizumab 和 avelumab 之间的差异.
主要方法:
- 对抗体PD-1/PD-L1复合物的结构特征的分析.
- 利用结晶学数据和计算软件进行详细的检查.
- 量化结合表面积和分子键的特征类型.
主要成果:
- 与nivolumab相比, pembrolizumab表现出更广泛的结构相互作用 (键,结合表面积),这可能解释了不同的临床结果.
- 在PD-L1和抗体durvalumab,atezolizumab和avelumab之间观察到蛋白质-蛋白质相互作用的显著变化.
- 特定的结构差异与每个抗体的独特结合特征相关.
结论:
- 抗体和PD-1/PD-L1之间的不同蛋白质蛋白质相互作用是显而易见的.
- 这些相互作用差异可能是临床活性观察到的变异的基础.
- 需要进一步的研究才能确定结构相互作用和临床疗效之间的确切联系.
关键词:
在PD-1中使用PD-1.在PD-L1中.它们是Atezolizumab.在此之前,Avelumab.达尔瓦卢马布 (Durvalumab) 是一种耐药的药物.这就是尼沃卢马布 (nivolumab).这就是Pembrolizumab.更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
1.3K
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
15.2K
相关概念视频
Antibody Actions
1.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.1K
Protein-protein Interfaces
12.5K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
12.5K
Affinity and Avidity
36.1K
Overview
36.1K
Factors Affecting Protein-Drug Binding: Drug Interactions
163
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
163
Antibody Structure
60.2K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
60.2K
